A teal peptide-like signal beside a membrane receptor-like cup.

Mechanisms & hormones

Glucagon-like peptide-1 (GLP-1)

Also found as: GLP-1 · GLP1 · glucagon-like peptide-1

In plain language

The peptide signal whose receptor is targeted by GLP-1 receptor agonists. The STEP 1 extension describes semaglutide as a GLP-1 analogue.[1]

Source check: 2026-10-04 · Editorial method

How the research uses this term

The STEP 1 extension followed weight and cardiometabolic measures after the semaglutide treatment period ended. The active-treatment phase had compared semaglutide with placebo alongside lifestyle intervention.[1]

Reading the evidence

The tirzepatide biomarker paper distinguishes GLP-1 receptor activity from combined GIP and GLP-1 receptor activity. A shared receptor target does not make the two study interventions identical.[2]

Used in our guides

Continue reading where this term appears.

References

Definitions and explanations are paraphrased. The source locations below identify the supporting passages and methods.

  1. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extensionPrimary research · Human trial extension · 2022DOI: 10.1111/dom.14725

    Source locations: Introduction; Materials and Methods.

    Review status · Pending
    Source packet file

    Weight_regain_and_cardiometabolic_effects_after_withdrawal_of_semaglutid_35441470_PMC9542252.pdf

  2. The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetesPrimary research · Human trial biomarker analysis · 2020DOI: 10.1111/dom.14174

    Source locations: Introduction and Materials and Methods.

    Review status · Pending
    Source packet file

    The_dual_glucose_dependent_insulinotropic_peptide_and_glucagon_like_pept_33462955_PMC7756479.pdf